Abstracts tagged "interstitial lung disease and scleroderma"

Abstract Number: 1115 • 2018 ACR/ARHP Annual Meeting
In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Shiwen Xu¹, David Abraham³, Olivier Lacombe⁴, Pierre Broqua⁴, Jean-Louis Junien⁴, Irena Konstantinova⁵ and Christopher P. Denton⁶, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Inventiva, DAIX, France, ⁵Inventiva, Daix, France, ⁶University College London, London, United Kingdom
Background/Purpose: The TbRIIDk-fib transgenic (TG) mouse model of scleroderma carries a fibroblast-specific transforming growth factor β (TGFβ) receptor II mutation resulting in balanced up-regulation of…
Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 2966 • 2015 ACR/ARHP Annual Meeting
Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience
Ranadeep Mandhadi¹ and Santhanam Lakshminarayanan², ¹Division of Rheumatology, The University of Connecticut Health Center, Farmington, CT, ²Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Systemic Sclerosis (SSc) is a rare heterogeneous autoimmune connective tissue disease.Pulmonary involvement is the major cause of mortality and morbidity in Systemic sclerosis. The…
Abstract Number: 2984 • 2015 ACR/ARHP Annual Meeting
Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity: Correlation with Pulmonary Function
Merrideth Ashley Morris¹, Tanjina Akter², Paul Nietert³, Galina S. Bogatkevich² and Richard Silver⁴, ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Public Health Science, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc). In addition to demonstrating dramatically high levels…
Abstract Number: 1679 • 2014 ACR/ARHP Annual Meeting
A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma
Jyoti Parida¹, Alok Nath², Zafar Neyaz³ and Vikas Agarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose We conducted a single center double-blind, randomized, placebo-controlled trial to determine the effects of oral Tadalafil on lung function and health-related symptoms in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].